Obsidian Therapeutics, Inc. Common Stock (NASDAQ:OBX) — Market Cap & Net Worth
Market Cap & Net Worth: Obsidian Therapeutics, Inc. Common Stock (OBX)
Obsidian Therapeutics, Inc. Common Stock (NASDAQ:OBX) has a market capitalization of $1.05 Billion ($1.05 Billion) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8654 globally and #2491 in its home market, demonstrating a 1.07% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Obsidian Therapeutics, Inc. Common Stock's stock price $17.00 by its total outstanding shares 61772876 (61.77 Million). Also see how large is Obsidian Therapeutics, Inc. Common Stock's balance sheet for a full breakdown of the balance sheet.
Obsidian Therapeutics, Inc. Common Stock Market Cap History: 2026 to 2026
Obsidian Therapeutics, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $1.05 Billion to $1.05 Billion (0.00% CAGR). Also see OBX operating cash flow for how efficiently the company converts equity into cash flow.
Obsidian Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Obsidian Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check OBX stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of OBX by Market Capitalization
Companies near Obsidian Therapeutics, Inc. Common Stock in the global market cap rankings as of September 17, 2026. Explore OBX year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Key companies related to Obsidian Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Obsidian Therapeutics, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Obsidian Therapeutics, Inc. Common Stock's market cap moved from $1.05 Billion to $ 1.05 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Obsidian Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.05 Billion USD |
| MoneyControl | $1.05 Billion USD |
| MarketWatch | $1.05 Billion USD |
| marketcap.company | $1.05 Billion USD |
| Reuters | $1.05 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Obsidian Therapeutics, Inc. Common Stock
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform de… Read more